Arc 2Sanqing’s Breakthrough
Wei Kang built Sanqing Pharmaceutical through overseas licensing, new business ventures, and the fight to bring its anti-cancer drug to patients despite corporate and regulatory obstruction. After the drug won public attention and approval, Wei Kang left the arc negotiating an affordable domestic price with medical insurance officials.
- Wei Kang signed a $3 billion overseas licensing agreement with Pfizer and directed Sanqing to expand production, research, and its future product lines.
- Sheng Changya warned Wei Kang that Shiseido might acquire the Whitening Drug formula to eliminate a competitor, so Wei Kang rejected Shiseido and Procter & Gamble’s offers and asked Sheng to build a domestic cosmetics brand.
- Wei Kang developed liver-protection capsules from an abandoned formula and planned new health supplement, cosmetics, and pharmaceutical businesses as Pfizer transferred its initial payment.
- Jian Guohua recommended Sanqing’s anti-cancer drug to Qi Zhengyang’s family, and the drug stabilized Qi after surgery revealed his cancer had spread to his brain.
- Merck obstructed the drug’s FDA application, but Qi publicly credited Sanqing with curing his cancer, and Mabus’s campaign led to FDA head Josen’s arrest.
- Wei Kang announced that Sanqing’s drug had been approved and would launch in China, while Li Senqiang exposed He Shan’s false accusations about Sanqing’s treatment of overseas patients.
- Wei Kang told the medical insurance negotiation team that Sanqing would price its drug below Keytruda, then offered caps of 200,000 yuan for employee insurance and 150,000 yuan for resident insurance.
- Chen Linghui accepted Wei Kang’s proposed prices, and the teams began discussing the procurement plan as the hall applauded.